Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Figure 4

CEAC, cost per QALY pemetrexed compared to docetaxel as the reference. CEAC: cost-effectiveness acceptability curve; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio.

The cost effectiveness acceptability curve demonstrates the likelihood of pemetrexed being cost-effective compared to docetaxel at each ICER threshold value for cost per QALY and cost per LYG.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us